Xiaodong Yang MD MS
Cardiothoracic Anesthesiology, Critical Care Medicine
Mount Sinai/ Cedars Sinai
Join to View Full Profile
8700 Beverly BlvdWest Hollywood, CA 90048
Phone+1 310-423-5841
Fax+1 310-423-0387
Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Adult Cardiothoracic Anesthesiology, 2010 - 2011- Icahn School of Medicine at Mount SinaiFellowship, Critical Care Medicine, 2009 - 2010
Johns Hopkins UniversityResidency, Anesthesiology, 2005 - 2009
Flushing Hospital Medical CenterResidency, Internal Medicine, 2002 - 2005
West China University of Medical SciencesClass of 1994
Certifications & Licensure
CA State Medical License 2011 - 2025
NY State Medical License 2010 - 2025
American Board of Anesthesiology Anesthesiology
Publications & Presentations
PubMed
- 4 citationsOvert Disseminated Intravascular Coagulation with Severe Hypofibrinogenemia During Veno-Venous Extracorporeal Membrane Oxygenation.Stephen Yang, Brittney Williams, David Kaczorowski, Michael Mazzeffi
The Journal of Extra-Corporeal Technology. 2022-06-01 - 1 citationsThrombopoietin, Soluble CD40 Ligand, and Platelet Count During Veno-arterial Extracorporeal Membrane Oxygenation.Michael A. Mazzeffi, Reney Henderson, Elizabeth K. Powell, Erik Strauss, Brittney Williams
ASAIO Journal. 2021-06-02 - 1 citationsUtilization of Transverse Abdominis Plexus Block for Treatment of HeartMate II Left Ventricular Assist Device-Associated Pain.Antonio Hernandez Conte, J. Hajj, Stephen X. Yang, E. Passano, H. Barone
Journal of Cardiothoracic and Vascular Anesthesia. 2017-12-02
Press Mentions
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 15th, 2022- Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with ChemotherapyJune 6th, 2022
- Apexigen to Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 MelanomaNovember 9th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
